Podcast Summary: Drug Story – "On Tuberculosis" (with John Green)

Host: Thomas Goetz
Guests: John Green (author, YouTuber), Dan Weissman (host of An Arm and a Leg), Emily Pisacreta, Tahir Amin, Pumeza Tisile
Date: February 17, 2026

Episode Overview

This episode of Drug Story investigates the tangled history and present-day challenges of tuberculosis (TB)—with a particular focus on the life-saving drug bedaquiline, the corporate patent system, and the global movement attempting to make TB drugs affordable and accessible. The episode, hosted primarily by Dan Weissman and featuring bestselling author and advocate John Green, highlights how patients, lawyers, and a worldwide community of "nerdfighters" confronted pharmaceutical giant Johnson & Johnson over drug patents that restrict access to vital TB medication.

Key Discussion Points & Insights

1. The Power and Flaws of Drug Innovation

• Historical Context of TB
  • Host Thomas Goetz recounts the history of TB, referencing his book The Remedy:

    "Since Koch's discovery of the bacteria in 1882, more than a billion people have died of the disease, even with antibiotics. Even today, people die of TB—more than a million people a year." (01:40)

  • TB's initial "cure" by Koch was debunked; true breakthroughs came with streptomycin (1943) and other antibiotics.
  • Despite effective drugs, TB remains deadly, especially in Asia, Africa, and India.

2. John Green's TB Activism and Community Impact

• Personal Connection and Storytelling

  • John Green shares his experience visiting a TB hospital in Sierra Leone, where he met a child, "Henry," who was actually a 16-year-old stunted by TB and desperately needed access to bedaquiline.

    “He was just really stunted and emaciated by tuberculosis... if we can't get the new treatment cocktail to him, he has a very low chance of survival.” (12:20–13:19)

  • This life-and-death encounter drove John Green’s obsession with tackling TB and its global inequities.

• Mobilizing the Nerdfighters

  • Green leveraged his online following to highlight that Johnson & Johnson was using secondary patents to keep monopolizing bedaquiline and thus keeping it out of reach for millions in poorer countries.

    "The only reason Johnson & Johnson executives think they can get away with this is that they think we aren't paying attention..." (04:37)

  • Within a week, Johnson & Johnson responded by allowing a cheaper generic to be distributed more widely—a testament to advocacy’s power but also its limitations.

3. How Pharmaceutical Patenting Works Against Public Health

• Patent Thicketing/Evergreening Explainer

  • Emily Pisacreta and Tahir Amin explain how pharma companies file dozens (or even over a hundred) overlapping patents to extend exclusivity and maximize profits.

    “74 patents could have lasted until 2031.” (17:00) “The 12 best-selling drugs in the US had an average of 131 patents each. If all of those patents stick, that's an average of 38 years of patent protection.” – Tahir Amin (19:18)

  • This "life cycle management" keeps drug prices high and generics off the market—impacting not only Americans but the entire world.

• Bedaquiline’s Case

  • Johnson & Johnson filed a secondary patent on a "salt formulation" of bedaquiline four years after the original, extending their monopoly.

    "The most important was the original formula... the second most important was the salt formulation..." (20:11)

  • Filing secondary patents late in the drug development process is strategic; it delays generic competition.

4. India’s Legal Fight: Section 3D and Global Implications

• Birth of Section 3D

  • Indian activists and lawyers (notably Tahir Amin) secured a law stating additional patents for known drugs must show increased efficacy—making it harder for companies to "evergreen."

    “If you are going to try and patent a new formulation... you have to prove that it increases the drug’s efficacy…” – Emily Pisacreta (27:11)

  • After years of legal struggle, in March 2023, India’s patent office rejected Johnson & Johnson’s secondary patent on bedaquiline, clearing the way for generic manufacture.

    "India rejected Johnson & Johnson’s secondary patent on bedaquiline." (31:01)

• TB Survivors as Advocates

  • Survivors like Pumeza Tisile and Nandita Venkateshan led the fight, bringing personal stakes to the legal battle.

    “Fumesa could see her lips moving, but couldn’t hear her voice... Like about half the people given this treatment, she lost her hearing for good.” (29:46)

5. The Global South's Influence on US Patent Thinking

• Reverse Advocacy
  • Global South’s strategies—like India’s Section 3D—are now informing advocacy efforts in the United States, aiming to reform the US patent landscape that still drives up global drug prices.

    “US drug companies shaped the World Trade Organization policies regarding drug patents, the policies that force places like India to recognize patents…” – Emily Pisacreta (37:08)

  • IMak (Initiative for Medicines Access and Knowledge) has shifted its focus largely to US advocacy.

6. Reflection on Activism, Advocacy, and Hope

• Incremental Gains Matter
  • Both John Green and Tahir Amin note that progress can be slow, and no single victory is ever enough—each step forward matters.

    “It's like you’re trying to move the ocean and you have a little bucket… And I find a lot of beauty in that.” – John Green (40:16)

  • Ultimately, activism needs both immediate direct action (such as the nerdfighter mobilization) and deep structural reform (legal and policy challenges).

Notable Quotes & Memorable Moments

• On hope and powerlessness:

  “I felt powerless before it... It was the first thing I thought about in the morning and the last thing I thought about before I went to sleep: How did we end up in a world where the world's deadliest infectious disease is largely ignored in the richest parts of the world?” – John Green (22:43–23:02)

• On evergreening:

  “Activists and experts call this kind of thing patent thicketing or evergreening... Drug companies call it life-cycle management.” – Dan Weissman (19:37–19:42)

• On social benefits of patents:

  "The social benefit actually goes up when you get the initial sort of a certain period of protection. But once you start stretching it out, the social benefit goes down." – Tahir Amin (37:56)

• On global influence:

  "The US is the heart of the global patent regime. US drug companies shaped the World Trade Organization policies... and it's U.S. patent officers who train examiners around the world." – Emily Pisacreta (37:08)

• On incremental activism:

  "It's like you're trying to move the ocean and you have a little bucket... but I am going to go ahead and fill up this bucket and walk a hundred feet and pour it in the ditch and then I'm going to walk back to the ocean... and I find a lot of beauty in that." – John Green (40:16)

• On collective action:

  "When tens of thousands of people do something insignificant together, it becomes very significant." – John Green (43:19)

Key Timestamps for Important Segments

• 00:01–03:40 – Thomas Goetz gives the history of TB and sets the stage for the episode and handoff to Dan Weissman/John Green.
• 03:45–08:09 – Dan Weissman introduces John Green and his online influence; background on the nerdfighter community.
• 10:41–13:19 – John Green recounts his visit to the TB hospital in Sierra Leone and the story of "Henry."
• 16:26–19:18 – Emily Pisacreta and Tahir Amin explain patent thicketing with insulin and other US drug examples.
• 20:11–21:57 – Technical discussion of bedaquiline’s salt formulation patent and patent strategies.
• 24:45–27:23 – History of India's Section 3D and its impact on drug patents.
• 29:03–31:40 – Fumesa Tisile’s account of her TB experience and the MSF-led legal challenge in India.
• 33:25–34:23 – John Green’s “Barely Contained Rage” video and its community impact.
• 36:12–39:11 – Tahir Amin on why India’s precedent must inform global and US patent reform.
• 40:16–41:14 – John Green’s reflection on movement-building and incremental change.
• 43:19 – John Green's call to action for collective bucket-moving activism.

Takeaways

• The story of bedaquiline and TB is emblematic of the wider global fight over drug patents, access, profit, and innovation.
• "Patent thickets" and evergreening practices keep essential drugs out of reach for millions—even when they could be produced cheaply.
• Grassroots and legal advocacy, as seen in India and through John Green’s nerdfighter community, can create real (if limited) change.
• Deep, systemic reform of the global patent regime, with lessons drawn from the Global South, is necessary for true health equity.